AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02253446
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
Trial: NCT02253446
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
Trial: NCT00002696
Drug: CAF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002696
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002696
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002696
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002696
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002696
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01464437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01220817
Drug: 3 POMx capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 POMx capsules daily
Trial: NCT00688012
Drug: SPC3649
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00818181
Drug: Biological: AL0206st
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03359590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment consists of placebo tablets for up to 24 weeks.
Trial: NCT04047654
Drug: Non vitamin K oral anticoagulants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
Trial: NCT01220817
Drug: 1 POMx capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 POMx capsule daily
Trial: NCT02267343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01741727
Drug: ABT-414
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-414 will be administered by intravenous infusion.
Trial: NCT03910244
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be given.
Trial: NCT02636595
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 coformulated with ABT-530
Trial: NCT00072839
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo solution injected subcutaneously
Trial: NCT00998296
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR inhibitor
Trial: NCT00998296
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF inhibitor
Trial: NCT00880919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Trial: NCT00982007
Drug: IV Iron (standard of care)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV standard of care (other IV iron) per the Investigator's discretion
Trial: NCT03131375
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
Trial: NCT02780180
Drug: QGC001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02780180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
Trial: NCT01416987
Drug: Pergoveris®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.
Trial: NCT00814502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
Trial: NCT03065023
Drug: MK-4621
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
Trial: NCT00705432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
Trial: NCT02454387
Drug: Placebo Part A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: ONO-4474 Part A2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: Placebo Part A2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: Placebo Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: Placebo Part C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: Placebo Part D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02331680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02185131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
Trial: NCT00283517
Drug: antipsychotics
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT03722238
Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Trial: NCT02730975
Drug: AA reduced dose-fat diet (B)
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
Trial: NCT03107871
Drug: Simple Syrup
RxNorm normalized name: Simple syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
Trial: NCT01493154
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
Trial: NCT00012350
Drug: FTI
RxNorm normalized name: Keftid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01293734
Drug: Theophylline Sustained-release Tablets and budesonide suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
Trial: NCT00618046
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00740129
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg intravenous infusion once
Trial: NCT02706015
Drug: Cefaliv® & Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
Trial: NCT02706015
Drug: Neosaldina® & Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
Trial: NCT02158546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Trial: NCT00860860
Drug: TF2
RxNorm normalized name: PROSOURCE TF20 LIQUID,ORAL,60ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TF2: 75-300 mg
Trial: NCT02057250
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dispensed according to local practice.
Trial: NCT03771664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as capsules.
Trial: NCT02120898
Drug: Zyclara®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream, brand product.
Trial: NCT02120898
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
Trial: NCT00831181
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
Trial: NCT00649038
Drug: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
RxNorm normalized name: benazepril hydrochloride / hydrochlorothiazide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fed
Trial: NCT00649038
Drug: Lotensin HCT® Tablets 20 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fed
Trial: NCT01635296
Drug: RO5045377
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
Trial: NCT01635296
Drug: RO5045377
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
Trial: NCT00783068
Drug: GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
Trial: NCT00783068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
Trial: NCT01119118
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
Trial: NCT00483717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) placebo
Trial: NCT00417417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline subcutaneously at each treatment visit.
Trial: NCT01052337
Drug: anaesthetics: sevofluorane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5%of sevofluorane with air
Trial: NCT05023499
Drug: SYMPT-X Glutamine, Oral Powder for Reconstitution
RxNorm normalized name: SYMPT-X Glutamine, oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
Trial: NCT01652040
Drug: Testosterone Patches
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
Trial: NCT00439010
Drug: [123I] AV 39
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00598910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04048356
Drug: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Trial: NCT00828009
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT03022318
Drug: carbidopa-levodopa 25-100 mg tablets
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions
Trial: NCT00399906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once daily, 12 weeks
Trial: NCT02281916
Drug: P28GST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of 100 µg of P28GST within 3 months (one injection per month)
Trial: NCT03236636
Drug: HUACHANSU PIAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
Trial: NCT04067817
Drug: norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient who was received the treatment of norepinephrine
Trial: NCT00734539
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
Trial: NCT04000633
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT04948372
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
Trial: NCT01378871
Drug: IMTOX-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7.
Trial: NCT02366546
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Trial: NCT00005068
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005068
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00421928
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo twice a day (BID) during 15 weeks
Trial: NCT01301157
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper quantity twice a day
Trial: NCT01301157
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper quantity twice a day
Trial: NCT02892344
Drug: QMF149 150/80 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QMF149 150/80 μg o.d via Concept1
Trial: NCT02892344
Drug: MF 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF 200 μg o.d. via Twisthaler®
Trial: NCT01780740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
Trial: NCT01376258
Drug: 5ARI
RxNorm normalized name: 5-alpha reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dutasteride or finasteride
Trial: NCT02608073
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
Trial: NCT02785549
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/8hours
Trial: NCT02785549
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/8 hours
Trial: NCT00072709
Drug: TCH346
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02202759
Drug: MLN0264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN0264 IV infusion
Trial: NCT00000285
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00755183
Drug: testosterone ophthalmic solution
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: testosterone ophthalmic solution for 128 days
Trial: NCT00755183
Drug: vehicle of testosterone ophthalmic solution
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vehicle of testosterone ophthalmic solution for 128 days
Trial: NCT02937116
Drug: IBI308
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937116
Drug: IBI308\Cisplatinum\Pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937116
Drug: IBI308\cisplatin\gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937116
Drug: IBI308\oxaliplatin\capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937116
Drug: IBI308\etoposide\cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937116
Drug: IBI308\irinotecan\5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00148317
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
Trial: NCT00335777
Drug: Migranal nasal spray at 4 hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
Trial: NCT00533208
Drug: MK0524
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00248404
Drug: NB1011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01667107
Drug: Calogen®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03536390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00936715
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg tablet administered orally once daily
Trial: NCT06323655
Drug: Active Control Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT00309374
Drug: LPS 2ng/kg intravenous bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00309374
Drug: Simvastatin 80mg; administered daily p.o. over 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00309374
Drug: Rosuvastatin 40mg; administered daily p.o. over 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01840241
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01725100
Drug: GSK1120212B (Standard DMSO content)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.